Invest with us
Scott Batty
Address: 12 Hamada St.
Entrance A – Floor 2
Rehovot, Israel, 7670315
Tel: +972-8-9365727
Fax: +972-72-2134600

Our Team
  • Donna J. Edmonds Active Chairperson
    Ms. Edmonds has over 30 years of experience in both the provider and the industry side of the healthcare business, including positions such as Hospital Administrator (Director of Nursing), General Manager of a specialty physician group, and Senior Executive positions in Business Development, Sales and Marketing at Baxter International and Cardiovascular Strategic Business Unit of Inverness Medical Innovations (now Alere).
  • Dr. D. Scott Batty, Jr. CEO
    Dr. Batty holds an MD from Tufts University, trained as a multi-organ abdominal transplant surgeon, and served as Director of Liver Transplant until 2003. He then pursued a pharmaceutical career of increasing clinical and medical responsibilities at Enzon, Bristol-Myers Squibb, and most recently at Genzyme. Dr. Batty joined ImmunArray in September of 2011.
  • Prof. Irun Cohen Co-Founder & Senior Advisor
    Prof. Irun Cohen, MD, is an immunologist at the Weizmann Institute of Science and the inventor of the iCHIP concept. Dr. Cohen was awarded the German Robert Koch Prize, and was a recipient of the Dutch Boerhaave Professorship. He is a Highly Cited Researcher (ISI), with over 500 professional publications.
  • Dr. Pennina Safer General Manager
    Dr. Safer began her career at Genetics Institute and later was a part of the Healthcare Investment team at Concord Ventures and a Partner at Medica Venture Partners. Pennina received her PhD in Human Genetics from Yale University, and did a post-doctoral fellowship at the Roche Institute of Molecular Biology. She joined ImmunArray in December 2013.
  • Dr. Vered Daniel-Carmi Head of Biological R&D
    Dr. Vered Daniel-Carmi joined ImmunArray in September 2011. She Previously was a senior researcher and lab manager of the Gynecologic Research laboratory at the Sheba Medical Center.
    Dr. Daniel-Carmi holds a Bachelor of Science degree in Life Science from the Tel-Aviv University, Master of Science and PhD in Immunology from the Weizmann Institute of Science.
  • Karin M. Fredrikson VP of Strategic Initiatives
    Karin M. Fredrikson has 20 years of comprehensive experience in genomics research, clinical research and markets. Karin established and managed exploratory collaborations with the disruptive Next Generation Sequencing 454 Sequencing Technologies for Roche Diagnostics.
  • Steven J. Wallace Director of Operations
    Steven J. Wallace has more than 30 years of R&D and operations experience in the biotechnology, pharmaceutical and chemical industries, including senior positions at Insmed, Boehringer Ingelheim and Hoechst Celanese. Steve holds a B.S. in Chemical Engineering from The Georgia Institute of Technology and a MBA from The College of William and Mary.
  • Scientific Advisory Board
  • Patrick Arensdorf Senior Advisor
    Patrick Arensdorf is an In-vitro diagnostics industry executive specializing in the strategic positioning and development of medical technologies. Pat received his B.A. in molecular biology from Princeton University and his Masters as a Sloan Fellow from Stanford Graduate School of Business.
  • Research and Strategic Collaborations
  • System Development
    Multiple indications expolred
  • Proof of Concept
  • System Design

  • ImmunArray develops in-vitro diagnostic (IVD) tests for personalized medicine utilizing platform biomarker technology with a broad range of applications. Its first two products are blood tests for early diagnosis of lung cancer and detection and monitoring of heart attacks.  The company’s proprietary iCHIP system measures the repertoires of auto-antibodies in a drop of blood using microarray technology.


    - The global in-vitro diagnostic market was valued at $46 billion and is expected to reach an estimated value of $74 billion in 2018.